Hims & Hers Health shares rise over 3% as international growth and GLP-1 launches boost subscriptions

Traders Union
All News
Stocks
Hims & Hers Health rises 3.01% today

Highlights

Hims & Hers Health expanded into Australia through the acquisition of Eucalyptus and began offering online prescriptions for GLP-1 weight-loss treatments.
The expansion boosted monthly revenue per subscriber by 21% year-over-year, but gross profit margins temporarily declined during the period.
Shares of Hims & Hers Health trade below key short-term moving averages with technical signals indicating continued selling pressure and an expected price range of $27.5 to $31.09 over the next five days.

Australian entry and telehealth expansion drive revenue, compress margins

Hims & Hers Health has expanded into Australia by acquiring Eucalyptus, an Australian digital health platform, and launching online prescriptions for GLP-1 weight-loss drugs and other treatments. This move, particularly through the telehealth brand Pilot, has increased subscriptions and delivered a 21% rise in monthly revenue per subscriber year-over-year. The expansion led to a temporary decline in gross profit margins, as referenced in the second-quarter earnings call. The company continues to offer a broad range of telehealth services across multiple health categories.

Anton Kharitonov, expert at Traders Union, views Hims & Hers Health’s latest gains with skepticism. He notes that subscriber growth and international expansion drive positive headlines, but points out persistent technical weaknesses. The stock remains under short-term moving averages, and momentum oscillators paint a clear picture of persistent selling pressure. Kharitonov is also concerned about the temporary decline in profit margins due to the Eucalyptus acquisition, calling it an early warning. He concludes, "Despite bullish narratives, I remain unconvinced until price action reclaims key levels and margin recovery is visible."

Viktoras Karapetjanc, expert at Traders Union, highlights the company’s strong international momentum and strategic positioning in digital health. He sees the Eucalyptus acquisition and GLP-1 prescriptions driving significant value and boosting recurring revenues. Despite near-term technical resistance, Karapetjanc believes the broader growth story is intact, with improved fundamentals and expanding markets. He asserts, "With the bullish structure in place and robust engagement from Australian expansion, I see further growth potential ahead."

Jainam Mehta, market strategist, observes that Hims & Hers Health is locked in a range with conflicting short- and long-term signals. He notes that oscillators favor sellers, but price action near the session high and above the 200-day moving average could prompt contrarian trade setups. Mehta suggests waiting for a decisive break above $29.32 or below $28.5 for tactical entries. He adds, "I’d watch for a potential breakout, as divergence in momentum may enable quick tactical plays within the $27.5–$31.09 band."

Short-term selling pressure persists as momentum signals contradict highs

Hims & Hers Health is trading below both its 20-day and 50-day moving averages ($30.3 and $31.89), indicating short-term selling pressure, but remains above the 200-day moving average at $28.5, suggesting ongoing longer-term bullish alignment. The near-term resistance is at $29.32 (Ichimoku Kijun), while key support stands at $28.5 (MA-200). Momentum indicators are largely negative: the MACD and ADX signal a weakening trend, and the RSI, CCI, and Awesome Oscillator all indicate selling conditions. The Stochastic RSI is neutral, and Bull/Bear Power (BBP) highlights intraday seller control, moving into oversold territory. Although the stock trades near its session high with 4.30% intraday volatility and a strong intraday tone, these oscillator readings contradict the price action.

Earlier, analysts noted that Hims & Hers Health was showing persistent technical weakness despite its international expansion efforts. The current analysis strengthens this view, highlighting that ongoing short-term resistance and negative momentum indicators warrant close monitoring of the $28.5 support level for potential downside risk.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.